RJT
VKTX icon

Raymond James Trust’s Viking Therapeutics VKTX Stock Holding History

Raymond James Trust’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$279K Buy
+4,410
New +$259K 0.01% 1077
2024
Q2 		– Sell
-3,371
Closed -$276K – 1304
2024
Q1 		$276K Buy
+3,371
New +$150K 0.01% 1022

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Raymond James Trust's VKTX Position: Q3 2024 in Review

Raymond James Trust opened a new position in Viking Therapeutics (VKTX) in Q3 2024: 4,410 shares worth $279K. The stake represents 0.01% of the portfolio and ranks #1077 among its holdings. This is a return to the name: Raymond James Trust previously reported a position in VKTX as recently as Q1 2024.

Raymond James Trust first reported a position in VKTX in Q1 2024 and has held it in 2 quarters since. 422 funds tracked by Wall St. Rank hold VKTX as of Q3 2024.

  • Raymond James Trust held 4,410 shares of Viking Therapeutics worth $279K as of Q3 2024.
  • Viking Therapeutics was a new Raymond James Trust position in Q3 2024.
  • Viking Therapeutics made up 0.01% of Raymond James Trust's portfolio in Q3 2024, its #1077 holding.
  • Raymond James Trust first reported a position in Viking Therapeutics in Q1 2024 and has held it in 2 quarters since.
  • 422 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2024.

Based on Raymond James Trust's 13F filing for Q3 2024, filed 12 Nov 2024.